Immucor, a provider of automated instrument-reagent systems, has reported a net income of $19.46 million, or $0.27 per diluted share, for the fiscal third quarter ended February 28, 2009, compared to $19.27 million, or $0.27 per diluted share, for the same period last year.
Subscribe to our email newsletter
Revenue for the fiscal third quarter of 2009 was $75.31 million, an increase of 12%, compared to $67.03 million for the prior-year period.
For the first nine months of fiscal 2009, revenue was $221.51 million, compared with $192.58 million in the prior-year period. Net income was $56.75 million, or $0.80 per fully diluted share, for the nine months ended February 28, 2009, compared with $53.18 million, or $0.75 per fully diluted share, for the nine months ended February 29, 2008.
Gioacchino De Chirico, Immucor’s president and CEO, said: “We are pleased with the stability of our performance given the current economic environment. The demand for our reagent products, which account for nearly 90% of our total revenue, has remained stable as shown by our earnings and our cash flow.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.